Omeros Corporation (NASDAQ:OMER – Free Report) – Equities research analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Omeros in a report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, up from their prior forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Omeros’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.94) EPS, FY2028 earnings at $2.43 EPS, FY2029 earnings at $4.30 EPS and FY2030 earnings at $5.47 EPS.
Omeros (NASDAQ:OMER – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $4.19 million.
Read Our Latest Stock Analysis on Omeros
Omeros Stock Performance
Shares of NASDAQ OMER opened at $11.70 on Tuesday. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The firm’s 50 day moving average price is $12.27 and its 200 day moving average price is $11.45. The firm has a market cap of $846.85 million, a P/E ratio of 16.71 and a beta of 2.66.
Institutional Trading of Omeros
A number of hedge funds have recently bought and sold shares of OMER. State of Wyoming acquired a new position in shares of Omeros in the 4th quarter valued at $25,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Omeros in the 4th quarter valued at $33,000. Assetmark Inc. acquired a new position in shares of Omeros in the 1st quarter valued at $38,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Further Reading
- Five stocks we like better than Omeros
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
